FDA to ease restrictions on peptides, NY Times reports

The FDA is moving toward allowing compounding pharmacies to produce over a dozen injectable peptides that were previously banned due to safety concerns, The New York Times’ Christina Jewett and Dani Blum reports. In 2023, 14 such peptides, unapproved by the FDA and marketed with unproven cosmetic, anti-aging, or disease-fighting claims, were removed from the list of compounds these pharmacies could legally produce for individualized patient use. Health Secretary Robert F. Kennedy Jr. has said in recent podcast appearances that he is pushing for the F.D.A. to reverse the prohibition on the peptides, which include some that act as growth-hormone stimulators. Shares of Hims & Hers, which sells peptide-based products, are up nearly 4% in morning trading to $19.47.